Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
HEAD AND NECK: Oropharynx: HPV+: Early Stage: XRT: HN 005

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Title
NRG Oncology HN005 (Oropharynx deintensification)
Study Title

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Site Link
Malignancy
Head and Neck, Oropharyx, Oropharyngeal cancer
Stage
Disease Setting
Definitive chemoradiation
Line Of Therapy
N/A
Investigational Agent
Reduced dose radiation with chemo or IO
Drug Class
XRT
PI
Noam VanderWalde, MD
Sponsor
NRG Oncology
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Squamous cell carcinoma of the oropharynx
  • Measurable disease either in primary or lymph node
  • P16 posotive locally
  • T1-2N1M0 or T3N0-1M0
  • No more than 10 pack years of smoking history
  • ECOG PS 0-1
  • No T4 or N2
  • No recurrent disease
  • No supraclavicular nodes
  • No prior malignancy unless disease free for at least 3 years
  • No allergy to cisplatin
Objective
  • Primary
    • PFS
    • QoL
  • Secondary
    • Locoregional failure
    • Distant failure
    • OS
    • Safety
    • Locoregional Control
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
HPV positive (+)
Dosing Frequency
Control Agents
Study Protocol
Randomized
Yes
X